Nice

News

Otsuka’s lupus nephritis drug Lupkynis backed for NHS use

Patients in England and Wales with active lupus nephritis will soon be able to access treatment with Otsuka Pharma’s Lupkynis following a recommendation by the health tech

News

NICE backs use of Gilead/Kite CAR-T via Cancer Drugs Fund

A pair of new guidance documents from UK cost-effectiveness authority NICE could see hundreds of more blood cancer patients eligible for treatment with CAR-T therapies fro

News

NICE says yes to J&J, AbbVie first-line leukaemia regimen

Patients in England with chronic lymphocytic leukaemia (CLL) will be able to access a new combination therapy based on Johnson & Johnson’s Imbruvica plus AbbVie’s Venc

News

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

News

NICE rejects Ipsen’s Cabometyx in thyroid cancer

Ipsen’s Cabometyx should not be used by the NHS for patients with differentiated thyroid cancer who have either not responded to or are ineligible for radioactive iodine t

News

NICE backs Keytruda for incurable cervical cancer via CDF

Hundreds of NHS patients with an incurable form of cervical cancer will be able to get treatment using a combination regimen based on Merck & Co/MSD’s cancer immunothe